Start with your card
Your insurance card is the beginning of the story, not the answer. Coverage depends on the exact drug, prescribed use, plan, pharmacy and date. A drug covered for diabetes is not automatically covered for weight management. Ask for your plan’s current written criteria before counting on a price.
Four coverage paths
On a small screen, scroll the tables sideways to see every column.
| Coverage path | First question |
|---|---|
| Employer | Who sets the pharmacy benefit and handles appeals? |
| Marketplace | Is this drug and use on my plan’s formulary? |
| Medicaid | What does my state and managed-care plan cover? |
| Medicare | Does Part D cover my indication, or could Bridge apply? |
Employer plans: ask for the summary plan description and pharmacy benefit. A company administering the card may not set the benefit: some employers self-fund their plans. State insurance rules and federal rules can apply differently; ask who administers appeals. Marketplace: find the plan’s formulary, tier, preferred pharmacy and any prior authorization or step therapy. A Marketplace plan is not a promise that every weight-loss drug is covered.
Medicaid: rules and covered indications vary by state and plan. For a concrete example, Pennsylvania ended Medical Assistance coverage of GLP-1 drugs for overweight and obesity effective January 1, 2026; other indications may remain covered with prior authorization. Do not apply that state’s decision to another state. Ask your state program or managed-care plan about your exact prescription.
A reality check from employers
In KFF’s 2026 survey, among firms offering health benefits with at least 200 workers, 18% reported that their largest-enrollment plan covers GLP-1 drugs primarily for weight loss. By firm size: 16% for 200–999 workers, 29% for 1,000–4,999 and 33% for 5,000 or more. These are shares of firms, not the chance that any individual is covered. KFF, 2026
Read a formulary row
For example, suppose a plan lists Drug A as an injection in tier 3 with PA / ST / QL. Tier is the plan’s cost-sharing category; PA means prior authorization, usually submitted by the prescriber; ST means step therapy, requiring specified prior treatment or an approved exception; QL is a quantity limit. Ask whether the row applies to your diagnosis, strength and plan year, and request the actual criteria. A row alone is not an approval.
Medicare’s temporary Bridge
Medicare Part D may cover a drug for an eligible non-weight-loss indication under plan rules. Separately, the temporary Medicare GLP-1 Bridge runs July 2026 through December 2027 for qualifying adults with Part D who are not eligible for the drug through ordinary Part D. Medicare lists Foundayo tablets, Wegovy injection or tablets, and Zepbound KwikPen; Zepbound single-dose pens and vials are excluded. The listed pharmacy copay is $50 per 28- or 30-day supply for eligible participants.
Bridge eligibility includes age 18 or older, use with ongoing nutrition and physical activity, and BMI at initiation of at least 35; or at least 30 with one of specified conditions; or at least 27 with another specified condition. The full list and Part D exclusions matter. Your clinician submits the prescription and required authorization; having a qualifying BMI alone does not guarantee approval. Medicare’s page and CMS explain the details.
Medicare says this separate Bridge copay does not count toward the Part D deductible or out-of-pocket limit and cannot be reduced by Extra Help.
The BMI 30 group requires heart failure with preserved ejection fraction, uncontrolled high blood pressure or stage 3a-or-higher chronic kidney disease. The BMI 27 group requires prediabetes, a prior heart attack or stroke, or symptomatic peripheral artery disease. People with type 2 diabetes, moderate-to-severe obstructive sleep apnea, or noncirrhotic MASH with moderate to advanced liver scarring are ineligible for Bridge even if their plan denies coverage; ask about ordinary Part D and appeal rights.
What makes up the bill?
Add the separate pieces: care membership + covered or cash visits + labs + pharmacy cost + shipping or supplies. A subscription is not the medicine. Confirm in-network clinician and pharmacy, deductible remaining, copay versus coinsurance, days supplied and any annual out-of-pocket limit. A coupon or cash discount is not insurance coverage; ask whether it can be combined with your plan and whether the payment counts toward your deductible or limit.
Worked cost examples
Illustration A: an employer-plan member is quoted a $100 allowed drug cost after the deductible and 25% coinsurance. The drug share is $25 for that fill; a separate $40 visit makes $65. These figures are illustrative, not an actual price or promise. Before the deductible, the share could differ. A monthly care membership, if any, would be extra.
Illustration B: a Medicare Part D member meets all Bridge requirements and fills an eligible form. The stated pharmacy copay is $50 for one 28- or 30-day supply. If a separately billed visit costs the member $20, the example total is $70; that visit amount is hypothetical. Eligibility, authorization and actual visit cost must be confirmed.
In another illustrative calculation, the allowed price is $300, $100 of deductible remains, and the plan then charges 20% coinsurance. The patient pays $100 + 20% of the remaining $200 = $140 for this fill. If the same terms apply to the next $300 fill after the deductible is met, the share is $60. This example assumes the deductible applies and no other fees or limits.
Approved PA, high counter price? Ask the pharmacy to verify the exact drug, strength, network and claim response. Ask the plan how much deductible remains and request an itemized estimate; approval establishes authorization, not a guaranteed price.
Missing information, denial or exclusion?
A request for missing records is not necessarily a denial: ask what is missing and who must send it. If denied, get the written reason and criteria. A prior-authorization denial may be appealed with your clinician’s supporting records; a plan exclusion is a different problem, so ask whether an exception or appeal is available. HealthCare.gov describes internal and independent external review for eligible health plans. Follow the deadline and instructions on your own notice; urgent cases may have faster procedures.
For Marketplace plans, HealthCare.gov says an internal appeal must be filed within 180 days of the denial notice. Your notice supplies the applicable process and deadline.
| What happened? | Who can help and what to do |
|---|---|
| Claim rejected | Ask the pharmacy for the rejection code; call the plan to confirm the reason. |
| PA pending | Ask the prescriber what was submitted and the plan what records are missing. |
| PA denied | Obtain the written reason and deadline; ask the clinician about supporting records and appeal. |
| Plan exclusion | Ask the plan for the written benefit language and whether an exception or appeal is available. |
| Wrong pharmacy or strength | Ask the pharmacy and prescriber to check the prescription and the plan’s network and covered form. |
Make the calls
Call the number on your card: “Is this exact drug and form covered for my prescribed use? Is prior authorization or step therapy required? What is my cost at this pharmacy, before and after my deductible? What is the renewal deadline and appeal process?” Write down the date, representative, reference number and promised next step.
Ask your clinician: “What diagnosis and form are you prescribing? Can your team send the required records and tell me when the request is submitted? If denied, can we review the reason and appropriate alternatives?” Before renewal or a new plan year, recheck criteria, formulary, network, deductible and authorization expiration. Rules and prices can change.
This guide concerns U.S. coverage and is not a personal coverage determination. Use the plan’s written terms and your clinician’s advice for your situation.
Comparing care subscriptions too? See ourprovider comparison.
Sources
Medicare.gov·CMS·HealthCare.gov·Pennsylvania DHS·Olena Kholina / Unsplash·Unsplash License